CR11688A - Compuesto heterociclico - Google Patents

Compuesto heterociclico

Info

Publication number
CR11688A
CR11688A CR11688A CR11688A CR11688A CR 11688 A CR11688 A CR 11688A CR 11688 A CR11688 A CR 11688A CR 11688 A CR11688 A CR 11688A CR 11688 A CR11688 A CR 11688A
Authority
CR
Costa Rica
Prior art keywords
compound
heterociclical
diabetes
formulas
prevention
Prior art date
Application number
CR11688A
Other languages
English (en)
Inventor
Yoshihiro Banno
Ryoma Hara
Ryosuke Tokunoh
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR11688A publication Critical patent/CR11688A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Se describe un agente para la prevencion y tratamiento de diabetes, el cual tiene excelentes efectos medicinales. especificamente se describe un compuesto representado por la formula (I) o (IA) o una de sus sales. (En las formulas, los simbolos se definen como en la descripcion).
CR11688A 2008-03-05 2010-09-23 Compuesto heterociclico CR11688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008055250 2008-03-05
JP2009025511 2009-02-06

Publications (1)

Publication Number Publication Date
CR11688A true CR11688A (es) 2010-12-08

Family

ID=41056073

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11688A CR11688A (es) 2008-03-05 2010-09-23 Compuesto heterociclico

Country Status (21)

Country Link
US (1) US8436043B2 (es)
EP (1) EP2251326A4 (es)
JP (1) JP5465658B2 (es)
KR (1) KR101616140B1 (es)
CN (1) CN102015641B (es)
AU (1) AU2009220615B2 (es)
BR (1) BRPI0912245A2 (es)
CA (1) CA2717138A1 (es)
CO (1) CO6321238A2 (es)
CR (1) CR11688A (es)
DO (1) DOP2010000267A (es)
EA (1) EA019752B1 (es)
EC (1) ECSP10010526A (es)
GE (1) GEP20135844B (es)
IL (1) IL207757A (es)
MA (1) MA32171B1 (es)
MX (1) MX2010009736A (es)
MY (1) MY158982A (es)
NZ (1) NZ588011A (es)
WO (1) WO2009110520A1 (es)
ZA (1) ZA201006511B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
WO2009057784A1 (ja) 2007-11-01 2009-05-07 Takeda Pharmaceutical Company Limited 複素環化合物
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010050445A1 (ja) 2008-10-27 2010-05-06 武田薬品工業株式会社 二環性化合物
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
MA33159B1 (fr) 2009-03-10 2012-03-01 Takeda Pharmaceutical Derives de la coumarone
WO2011027849A1 (ja) * 2009-09-04 2011-03-10 武田薬品工業株式会社 複素環化合物
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CN102781914B (zh) * 2010-01-06 2014-09-17 武田药品工业株式会社 吲哚衍生物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
CN104744370A (zh) 2011-02-08 2015-07-01 辉瑞大药厂 胰高血糖素受体调节剂
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
ES2550345T3 (es) 2011-07-22 2015-11-06 Pfizer Inc. Moduladores del receptor de quinolinilglucagón
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013147026A1 (ja) 2012-03-29 2013-10-03 武田薬品工業株式会社 芳香環化合物
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
WO2018140338A1 (en) * 2017-01-24 2018-08-02 Alphala Co., Ltd. Amide compounds and use thereof
KR102021114B1 (ko) * 2017-01-24 2019-09-11 주식회사 엘지화학 페놀의 정제 방법
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
WO2023250316A1 (en) * 2022-06-22 2023-12-28 Ptc Therapeutics, Inc. Compounds for treating spinocerebellar ataxia type 3

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4793717A (en) 1982-05-06 1988-12-27 Minnesota Mining And Manufacturing Company Device for visually indicating a pressure or temperature condition
DE60017115T2 (de) 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amid-derivate und deren medizinische verwendung
ATE307798T1 (de) * 1999-05-17 2005-11-15 Novo Nordisk As Glucagon antagonisten/inverse agonisten
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
US7241785B2 (en) 2001-03-23 2007-07-10 Takeda Pharmaceutical Company Limited Five-membered heterocyclic alkanoic acid derivative
AU2002365622A1 (en) * 2001-12-03 2003-06-17 Novo Nordisk A/S Novel glucagon antagonists
EP1513817A1 (en) 2002-05-24 2005-03-16 Takeda Pharmaceutical Company Limited 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2004002480A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
ATE344036T1 (de) 2002-11-21 2006-11-15 Pharmacia & Upjohn Co Llc N-(4-(piperazin-1-yl)-phenyl-2-oxazolidinon-5- carbonsäureamid-derivate und verwandte verbindungen als antibakterielle mittel
EP1590336B1 (en) * 2003-01-27 2010-12-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
ATE482200T1 (de) * 2003-05-01 2010-10-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
EP1626717A4 (en) * 2003-05-09 2009-09-09 Merck & Co Inc BENZIMIDAZOLE, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
AU2005252183B2 (en) * 2004-06-04 2008-07-17 Merck Sharp & Dohme Corp. Pyrazole derivatives, compositions containing such compounds and methods of use
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
JP2008505905A (ja) * 2004-07-07 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
CN1993124A (zh) * 2004-07-22 2007-07-04 默克公司 取代吡唑、含有这种化合物的组合物及其应用
JP2006112549A (ja) 2004-10-15 2006-04-27 Jtekt Corp 自在継手
WO2006102067A1 (en) 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
ATE498358T1 (de) 2005-06-29 2011-03-15 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
JP5577006B2 (ja) 2005-07-01 2014-08-20 味の素株式会社 迅速スクリーニング方法及び該方法で得られた微生物
JP4990783B2 (ja) 2005-09-30 2012-08-01 Ｍｓｄ株式会社 ２−ヘテロアリール置換インドール誘導体
SI1951661T1 (sl) * 2005-11-17 2012-11-30 Lilly Co Eli Antagonisti glukagonskega receptorja priprava interapevtske uporabe
WO2007089031A1 (en) 2006-02-01 2007-08-09 Takeda Pharmaceutical Company Limited Piperidine derivatives as tachykinin receptor antagonists
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2009057784A1 (ja) 2007-11-01 2009-05-07 Takeda Pharmaceutical Company Limited 複素環化合物
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter

Also Published As

Publication number Publication date
EA201071032A1 (ru) 2011-06-30
CA2717138A1 (en) 2009-09-11
ZA201006511B (en) 2011-11-30
KR20100126470A (ko) 2010-12-01
DOP2010000267A (es) 2010-09-30
AU2009220615A1 (en) 2009-09-11
US20120270865A2 (en) 2012-10-25
US20120053173A1 (en) 2012-03-01
KR101616140B1 (ko) 2016-04-27
CN102015641A (zh) 2011-04-13
NZ588011A (en) 2012-06-29
ECSP10010526A (es) 2010-11-30
AU2009220615B2 (en) 2013-12-19
MX2010009736A (es) 2010-09-30
US8436043B2 (en) 2013-05-07
MA32171B1 (fr) 2011-03-01
GEP20135844B (en) 2013-06-10
EP2251326A4 (en) 2011-08-31
IL207757A0 (en) 2010-12-30
IL207757A (en) 2015-07-30
MY158982A (en) 2016-11-30
JP5465658B2 (ja) 2014-04-09
JPWO2009110520A1 (ja) 2011-07-14
AU2009220615A2 (en) 2010-11-11
WO2009110520A1 (ja) 2009-09-11
EA019752B1 (ru) 2014-06-30
CO6321238A2 (es) 2011-09-20
BRPI0912245A2 (pt) 2019-09-24
CN102015641B (zh) 2014-01-01
EP2251326A1 (en) 2010-11-17

Similar Documents

Publication Publication Date Title
ECSP10010526A (es) Compuesto heterociclico
CO6511251A2 (es) Compuestos quimicos
CO6592104A2 (es) Compuesto heterociclico
UY33756A (es) Compuesto biciclico
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
DOP2012000263A (es) Compuestos quimicos
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
EA201100037A1 (ru) Органические соединения
CR20150250A (es) Nuevos derivados de piridina
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
CR20120418A (es) Inhibidores de virus flaviviridae
EA201170772A1 (ru) Органические соединения
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
CU20110191A7 (es) Compuestos orgánicos y sus usos
CO7350640A2 (es) Compuestos diméricos
CR20150440A (es) Nuevos derivados de piridina
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
EA201401277A1 (ru) Соединения метантиона, обладающие противовирусной активностью
CL2015003037A1 (es) Derivados de triazina
UY32555A (es) Nuevos derivados de quinazolinadiona